Skip to main content

Table 3 Lipid modifying treatment of study population

From: First-line treatment patterns and lipid target levels attainment in very high cardiovascular risk outpatients

  Overall N = 712 LDL-C goal attainment N = 71 No LDL-C goal attainment N = 641 p-value
Monotherapy 476 (66.9) 43 (60.6) 433 (67.6) 0.2
Statin 465 (65.3) 43 (60.6) 422 (65.8) 0.4
Fibrate 4 (0.6) 0 (0) 4 (0.6) 1.0
Ezetimibe 7 (1.0) 0 (0) 8 (1.2) 1.0
Combination therapy 236 (33.1) 28 (39.4) 208 (32.4) 0.2
Statin + Ezetimibe 182 (25.6) 22 (31.0) 160 (25.0) 0.3
Statin + Ezetimibe + n3 fatty acids 24 (3.4) 2 (2.8) 22 (3.4) 1.0
Statin + n3 fatty acids 24 (3.4) 2 (2.8) 22 (3.4) 1.0
Other 6 (0.8) 2 (2.8) 4 (0.6) 0.1
% LDL-C reduction efficacy     0.5
low 42 (5.9) 4 (5.6) 38 (5.9)  
moderate 486 (68.3) 45 (63.4) 441 (68.8)  
high 160 (22.5) 18 (25.4) 142 (22.2)  
very high 24 (3.4) 4 (5.6) 20 (3.1)  
  1. Data are expressed as n (%).